Menu Search
Equities

Neogenomics Inc

NG9:DUS

Neogenomics Inc

Actions
  • Price (EUR)15.50
  • Today's Change1.00 / 6.90%
  • Shares traded0.00
  • 1 Year change-10.92%
  • Beta--
Data delayed at least 15 minutes, as of Nov 25 2024 07:11 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

NeoGenomics, Inc. provides a range of oncology diagnostic testing and consultative services which includes technical laboratory services. The Company offers professional interpretation of laboratory test results by licensed physicians who specialize in pathology and oncology. Its segments include Clinical Services and Advanced Diagnostics. The Clinical Services segment consists of clinical cancer testing; interpretation and consultative services; molecular and NGS testing, and comprehensive technical and professional services offering. Its Clinical Services customers include community-based pathology and oncology practices, hospital pathology labs, reference labs, and academic centers. The Advanced Diagnostics segment consist of clinical trials and research, validation laboratory services, and informatics. Its Advanced Diagnostics customers include pharmaceutical companies to whom it provides testing and other services to support their research studies and clinical trials.

  • Revenue in USD (TTM)644.12m
  • Net income in USD-77.73m
  • Incorporated1998
  • Employees2.10k
  • Location
    Neogenomics Inc9490 Neogenomics WayFORT MYERS 33912United StatesUSA
  • Phone+1 (239) 768-0600
  • Fax+1 (775) 329-0852
  • Websitehttps://neogenomics.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.